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Chlamydia pneumoniae, overall and cardiovascular mortality
in end-stage renal disease (ESRD).
Background. Cross-sectional and retrospective studies sug-
gest that Chlamydia pneumoniae infection may contribute im-
portantly to the high cardiovascular risk of patients with end-
stage renal disease (ESRD).
Methods. We investigated the relationship between C. pneu-
moniae serology and survival and incident fatal cardiovascular
events in a cohort of 227 ESRD patients (follow-up of 39 
20 months).
Results. On univariate Cox regression analysis patients with
anti-C. pneumoniae immunogloblulin A (IgA) titer 1:16 had
a significantly higher risk of all-cause and cardiovascular mor-
tality when compared to patients without IgA antibodies. How-
ever, after data adjustment for age and smoking, the hazard
ratio (HR) decreased substantially and became largely nonsig-
nificant. Adjustments for traditional and nontraditional risk
factors further decreased the independent association of IgA
anti-C. pneumoniae and these outcomes (all-cause mortality
HR, 1.08; 95% CI, 0.68 to 1.72; P 0.74; cardiovascular mortal-
ity HR, 1.07; 95% CI, 0.60 to 1.89; P  0.83). A similar loss
of prognostic power was observed for IgG anti-C. pneumoniae
so that in fully adjusted models the HRs were very close to
those observed for IgA anti-C. pneumoniae (all-cause mortality
HR, 1.13; 95% CI, 0.68 to 1.86, P 0.64; cardiovascular mortal-
ity HR, 1.10; 95% CI, 0.60 to 2.00; P  0.77).
Conclusion. C. pneumoniae seropositivity is associated to
shorter survival and incident fatal cardiovascular events in pa-
tients with ESRD but these associations are in large part attrib-
utable to the link between C. pneumoniae and well-established,
traditional risk factors. It is highly unlikely that C. pneumoniae
infection is a major risk factor in patients with ESRD.
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Cardiovascular mortality in patients with end-stage
renal disease (ESRD) is a problem of epidemic dimen-
sions [1, 2]. In recent years inflammation has emerged
as a major cardiovascular risk factor in this population
[3–6]. However, the cause of inflammation in ESRD is
still uncertain and hemodialysis-related, genetic, and in-
fectious causes have been implicated in this process [7].
It has been hypothesized that raised C-reactive protein
(CRP) may be an indicator of chronic infections possibly
correlated with risk of coronary heart disease, such as
bronchopulmonary infection with Chlamydia pneumon-
iae. In line with this possibility it was found that the
serum titre of anti-C. pneumoniae antibodies is directly
related to the severity of carotid atherosclerosis both in
patients with chronic renal diseases [8] and in dialysis
patients [5, 9]. Furthermore, a retrospective cohort study
of small dimensions has recently reported that the pres-
ence of anti-C. pneumoniae antibodies predicts survival
in patients treated by peritoneal dialysis [10].
Long-term prospective studies with data collected on
many possible confounders or mediators may help to
distinguish whether the link between C. pneumoniae and
cardiovascular complications is truly independent of other
risk factors since this approach is generally less influ-
enced than surveys and retrospective studies by any ef-
fect of preexisting disease itself on the factors being
investigated. We report the relationship between C. pneu-
moniae seropositivity and all-cause and cardiovascular
mortality in the Cardiovascular Risk Extended Evalua-
tion in Dialysis (CREED) study, an ongoing prospective
study aimed at investigating risk factors in the ESRD
population.
METHODS
Protocol
The protocol was in conformity to the ethical guide-
lines of our institutions and informed consent was obtained
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from each participant. All studies were performed during
a nondialysis day, between 8:00 a.m. and 10:00 a.m.
Study cohort
The inception cohort was enrolled between January
1997 and May 1998 and was composed of 227 patients
with ESRD (126 males and 101 females) without history
of congestive heart failure and without intercurrent ill-
nesses. These patients had been on regular dialysis treat-
ment for at least 6 months (median duration of regular
dialysis treatment, 42 months; interquartile range, 21 to
106 months). The prevalence of diabetes mellitus in this
cohort was 15% (i.e., 35 patients out of 227).
All patients were virtually anuric (24-hour urine vol-
ume 200 mL/day) and were being treated three times
a week with standard bicarbonate dialysis (sodium, 138
mmol/L; HCO3, 35 mmol/L; potassium, 1.5 mmol/L; cal-
cium, 1.25 mmol/L; and magnesium, 0.75 mmol/L) and
cuprophan or semisynthetic membranes (dialysis filters
surface area, 1.1 to 1.7 m2). The average urea Kt/V in
these patients was 1.21  0.27. Eighty-five patients were
habitual smokers (21 16 cigarettes/day). One hundred
and twenty-two patients were on treatment with erythro-
poietin. Eighty-three patients were being treated with
antihypertensive drugs [58 on monotherapy with angio-
tensin-converting enzyme (ACE) inhibitors, angiotensin
II type 1 receptors (AT-1) antagonists, calcium channel
blockers, and alpha and beta blockers and 25 on double
or triple therapy with various combinations of these
drugs]. After the initial assessment patients were fol-
lowed up for an average time of 39 months (range, 0.2 to
62.0 months). During the follow-up, fatal cardiovascular
events (myocardial infarction, heart failure, stroke, pul-
monary embolism, arrhythmia, sudden death, mesenteric
infarction, and peripheral vascular disease) and death
were accurately recorded. Each death was reviewed and
assigned an underlying cause by a panel of five physi-
cians. As a part of the review process, all available medi-
cal information about each death was collected. This
information always included study and hospitalization
records. In the case of an out-of-hospital death, family
members were interviewed by telephone to better ascer-
tain the circumstances surrounding death.
Laboratory measurements
Blood sampling was performed after an overnight fast
between 8.00 a.m. and 10.00 a.m. always during a nondial-
ysis day. After 20 to 30 minutes of quiet resting in semi-
recumbent position, samples were taken into chilled eth-
ylenediaminetetraacetic acid (EDTA) vacutainers, placed
immediately on ice, centrifuged within 30 minutes at
–4C, and the plasma stored at –80C before assay. Serum
lipids, albumin, calcium, phosphate, and hemoglobin
measurements were made using standard methods in the
routine clinical laboratory. CRP and plasma homocys-
teine were measured as reported elsewhere [5]. Immuno-
globulin G and A (IgG) and (IgA)-specific antibodies
for C. pneumoniae were determined by using a semi-
quantitative commercially available kit (Labsystems OY,
Helsinki, Finland), which is 100% specific and 97% sensi-
tive. This method was based on an indirect solid-phase
enzyme immunoassay with horseradish peroxidase as a
marker enzyme (intra-assay cardiovascular %, 4% to
6%). IgG and IgA C. pneumoniae antibody titers were
analyzed as three categories (IgG antibodies, undetect-
able, at a dilution of 1 in 32 and at a dilution of 1 in
64 and IgA antibodies, undetectable, at a dilution of 1
in 8 and at a dilution of 1 in 16).
Statistical analysis
Data are reported as mean  SD, median and inter-
quartile range, or as percent frequency and comparisons
between groups were made by one-way analysis of vari-
ance (ANOVA), Kruskal-Wallis test, or chi-square test,
as appropriate. The relationship between ordinal vari-
ables was tested by Spearman rank correlation.
The predictive power of IgG and IgA C. pneumoniae
titers for all-cause and cardiovascular mortality was ana-
lyzed by Cox’s proportional hazards models at different
levels of data adjustment: IgG or IgA titer only (unad-
justed); model 1  age- and smoking-adjusted; model
2  model 1  other Framingham risk factors (gender,
diabetes, systolic blood pressure, serum cholesterol, and
previous cardiovascular events). Furthermore, we forced
into model 2 (Framingham risk factor–based model) risk
factors peculiar to ESRD (serum albumin, hemoglobin,
and calcium x phosphate) and emerging risk factors (se-
rum CRP and plasma homocysteine). Hazard ratios
(HR) and their 95% confidence intervals (CI) were cal-
culated with the use of the estimated regression coeffi-
cients and their standard errors in the Cox regression
analysis. The assumption of linearity for the Cox models
was examined through visual inspection and no violation
of proportional hazards was found. There were no miss-
ing values for anti-C. pneumoniae antibodies. Ten pa-
tients had missing values for other covariates. Two were
missing cholesterol levels; one did not have hemoglobin
level; two did not have albumin measures; three were
missing calcium and phosphate; and two did not have
CRP values. Missing values for these covariates were set
to the mean value. All calculations were done using a
standard statistical package (SPSS for Windows, version
9.0.1, Chicago, IL, USA).
RESULTS
Eighty-nine patients (39%) were positive for IgA anti-
C. pneumoniae antibodies (1:8 in 24 cases and 1:16 in
the remaining 65 cases). One hundred and seventeen
patients (51%) were positive for IgG anti-C. pneumoniae
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Table 1. Somatometric, clinical, and biochemical data of patients divided on the basis of immunoglobulin A (IgA) anti-chlamydia titers
IgA anti-chlamydia titers
Seronegative 1:8 1:16
(N  138) (N  24) (N  65) P value
Age years 57.115.0 59.514.7 66.513.0 0.001
Males number (%) 69 (50%) 16 (67%) 41 (63%) 0.11
Diabetes number (%) 14 (10%) 6 (25%) 15 (23%) 0.02
Smokers number (%) 42 (30%) 12 (50%) 31 (48%) 0.02
Systolic blood pressure mm Hg 139.724.6 131.426.6 142.825.1 0.16
Diastolic blood pressure mm Hg 76.612.1 72.712.6 75.814.2 0.37
Cholesterol mmol/L 5.581.62 5.141.25 5.011.20 0.03
Hemoglobin g/L 108.118.6 108.819.2 106.118.7 0.73
Albumin g/L 42.15.1 41.84.1 40.34.3 0.04
Calcium mmol/L 2.310.27 2.200.26 2.220.20 0.04
Phosphate mmol/L 1.980.42 2.060.53 1.950.47 0.58
Patients with previous cardiovascular events number (%) 55 (40%) 9 (37%) 31 (48%) 0.52
Homocysteine lmol/L 26.7 (19.4–46.8) 26.9 (19.5–41.2) 27.5 (19.6–35.3) 0.70
C-reactive protein mg/L 7.8 (3.4–16.3) 4.5 (3.4–11.6) 8.2 (3.4–19.1) 0.24
Data are reported as mean  SD, median and interquartile range or as percent frequency, as appropriate.
antibodies (1:32 in 53 cases and 1:64 in the remaining
64 cases). On univariate analysis IgG and IgA C. pneu-
moniae antibodies were strongly interrelated (Spearman
rank, r  0.65, P  0.001). Patients with high titer of
IgA anti-C. pneumoniae antibodies (Table 1) were older,
more likely to be diabetics and smokers, and were char-
acterized by a lower serum total cholesterol, albumin,
and calcium and a higher proportion of males when com-
pared to remaining patients. When the study cohort was
reclassified on the basis of IgG anti-C. pneumoniae anti-
bodies patients with a high titer differed from those with
a low or normal titer for all but serum albumin and
calcium the above-mentioned risk factors.
IgG and IgA anti-C. pneumoniae titers, all-cause, and
cardiovascular mortality
During the 39  20 months of the follow-up period,
102 patients died, 69 of them (i.e., 68% of total deaths)
of cardiovascular causes (Table 2).
On univariate Cox regression analysis patients with
anti-C. pneumoniae IgA titer 1:16 had a significantly
higher risk of all-cause and cardiovascular mortality
when compared to patients without IgA antibodies (Ta-
bles 3 and 4 unadjusted model). However, after data
adjustment for age and smoking, the HR of IgA anti-C.
pneumoniae titers for all-cause and cardiovascular mortal-
ity decreased substantially and became largely nonsignifi-
cant (Tables 3 and 4, Model 1). Adjustments for other
traditional risk factors (gender, diabetes, cholesterol, hy-
pertension, and previous cardiovascular events) (Tables
3 and 4, Model 2) further decreased the independent
association of IgA anti-C. pneumoniae and these out-
comes. Forcing factors peculiar to ESRD (anemia, cal-
cium x phosphate product and albumin) and emerging
risk factors (CRP and homocysteine) into model 2 did
not modify the HR of IgA anti-C. pneumoniae (all-cause
Table 2. Causes of death in the study cohort
Number
Cardiovascular
Stroke 19
Myocardial infarction 16
Heart failure 14
Sudden death 7
Mesenteric infarction 5
Arrhythmia 4
Pulmonary embolism 3
Severe peripheral vascular disease 1
Total 69
Other causes
Sepsis/infection 10
Cachexia 7
Neoplasia 5
Hyperkalemia 4
Gastrointestinal hemorrhage 3
Diabetes, hyperosmolar coma 1
Treatment withdrawal 1
Chronic obstructive pulmonary disease 1
Hemoptysis 1
Total 33
mortality HR, 1.08; 95% CI, 0.68 to 1.72; P  0.74;
cardiovascular mortality HR, 1.07; 95% CI, 0.60 to 1.89;
P  0.83).
A similar loss of prognostic power was observed for
IgG anti-C. pneumoniae so that in statistical models ad-
justed for age and smoking the contribution of IgG anti-
C. pneumoniae titer to explain the incidence of these
outcomes was low and not significant (all-cause mortality
HR, 1.24; 95% CI, 0.78 to 2.00; P  0.36; cardiovascular
mortality HR, 1.23; 95% CI, 0.70 to 2.16; P  0.47).
Further adjustment for traditional risk factors produced
HRs very close to those observed for IgA anti-C. pneu-
moniae (all-cause mortality HR, 1.13; 95% CI, 0.68 to
1.86; P  0.64; cardiovascular mortality HR, 1.10; 95%
CI, 0.60 to 2.00; P  0.77).
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Table 3. Cox regression analysis: Immunoglobulin A (IgA) anti-chlamydia based model (all-cause death)
Model 1 (Age and Model 2 (Adjusted for
Variables (units of increase) Unadjusted smoking adjusted) Framingham risk factors)
IgA anti-chlamydia titer
0  seronegative 1a 1a 1a
1  IgA titre 1:8 1.22 (0.64–2.34), P  0.55 1.03 (0.54–2.00), P  0.92 0.99 (0.50–1.95), P  0.97
2  IgA titre 1:16 1.89 (1.25–2.87), P  0.003 1.21 (0.79–1.87), P  0.39 1.09 (0.69–1.71), P  0.72
Age (1 year) 1.05 (1.03–1.07), P  0.001 1.05 (1.03–1.07), P  0.001
Smoking 1.90 (1.27–2.85), P  0.002 1.43 (0.88–2.34), P  0.15
Male gender 1.78 (1.06–3.00), P  0.03
Diabetes 1.83 (1.14–2.95), P  0.01
Cholesterol (1 mmol/L) 1.06 (0.92–1.22), P  0.43
Systolic blood pressure (1 mm Hg) 1.00 (0.99–1.01), P  0.89
Previous cardiovascular events 2.25 (1.47–3.44), P  0.001
Data are expressed as hazard ratios, 95% CI, and P values.
a Reference group
Table 4. Cox regression analysis: Immunoglobulin A (IgA) anti-chlamydia based model (cardiovascular mortality)
Model 1 (Age and Model 2 (Adjusted for
Variables (units of increase) Unadjusted smoking adjusted) Framingham risk factors)
IgA anti-chlamydia titre
0  seronegative 1a 1a 1a
1  IgA titre 1:8 1.65 (0.82–3.34), P  0.16 1.40 (0.69–2.85), P  0.36 1.40 (0.67–2.94), P  0.37
2  IgA titre 1:16 1.77 (1.05–2.98), P  0.03 1.16 (0.68–1.98), P  0.58 1.00 (0.57–1.77), P  0.99
Age (1 year) 1.05 (1.03–1.08), P  0.001 1.05 (1.03–1.08), P  0.001
Smoking 2.24 (1.38–3.65), P  0.001 1.70 (0.94–3.05), P  0.08
Male gender 1.92 (1.00–3.67), P  0.05
Diabetes 1.77 (0.98–3.19), P  0.06
Cholesterol (1 mmol/L) 1.11 (0.94–1.32), P  0.21
Systolic blood pressure (1 mm Hg) 1.00 (0.99–1.01), P  0.46
Previous cardiovascular events 2.35 (1.39–3.98), P  0.001
Data are expressed as hazard ratios, 95% CI, and P values.
a Reference group
Combined analysis of IgA and IgG anti-C. pneumon-
iae antibodies (anti-IgA 1:16 and/or anti-IgG 1:64)
failed to materially increase the prediction power of chla-
mydia serology for all-cause (HR, 1.11; 95% CI, 0.68 to
1.83; P 0.68) and cardiovascular death (HR, 1.00; 95%
CI, 0.55 to 1.84; P  0.99) in Cox models, including all
Framingham risk factors.
DISCUSSION
This study shows that in ESRD high IgA and IgG
anti-C. pneumoniae titers are associated with shorter
survival and incident cardiovascular complications only
on crude analysis and that after simple adjustment for
age and smoking and other traditional risk factors the
relative risk of chlamydia seropositivity for all-cause and
cardiovascular mortality is of slight degree and largely
nonsignificant.
Cardiovascular risk factors in ESRD
Patients with ESRD have a high burden of traditional
(Framingham) risk factors. Indeed diabetes, hyperten-
sion, smoking, and alterations in the lipid profile are
highly prevalent in ESRD patients. In addition, risk fac-
tors peculiar to ESRD, like anemia [11] and high phos-
phate and calcium x phosphate product [12], as well as
emerging risk factors, like hyperhomocysteinemia [13, 14]
and microinflammatory processes [3–6], play an impor-
tant role in the high cardiovascular risk of these patients.
The causes of microinflammation and elevated CRP in
ESRD are largely unknown and because uremic patients
have compromised immune defense [15], it is suspected
that inflammation may be in part due to low-grade, sub-
clinical chronic infections [7].
Anti-chlamydia antibodies and cardiovascular
risk in ESRD
C. pneumoniae has been linked to atherosclerosis and
coronary heart disease in the general population but it
remains unclear whether this association entails a causal
link [16]. In 1999, we suggested that subclinical chlamyd-
ial infection may be implicated in atherosclerosis in
ESRD in that we found that IgG anti-C. pneumoniae
titer was related to serum CRP as well as to number
of atherosclerotic plaques [9] in the carotid arteries in
patients on chronic dialysis. In a subsequent study Sten-
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vinkel et al [4] reported an association between a high
IgA anti-C. pneumoniae titer with increased intima me-
dia cross-sectional area in patients with chronic renal
insufficiency maintained on conservative treatment. A
high IgA anti-C. pneumoniae titer has also been associ-
ated with larger carotid plaques [17] and progression
in intimal lesions in dialysis patients [18] and with the
angiographic presence of coronary heart disease in pa-
tients with chronic renal failure [19]. Very recently chla-
mydia IgG seropositivity has been related to coronary
calcium score and to increased intima media thickness
in a group of 39 patients with childhood-onset ESRD
[20]. In line with the hypothesis that chlamydia infection
may be an important risk factor for atherosclerotic com-
plications in ESRD, an association was found between
a high IgA anti-C. pneumoniae titer and cardiovascular
events in a small study in continuous ambulatory perito-
neal dialysis (CAPD) patients [10]. Of note in these
studies the relative risk for atherosclerosis or atheroscle-
rotic complications was high and ranged from 1.7 [19]
to 7.2 [10] The relationship between chlamydia serology
and cardiovascular outcomes has never been examined
in a prospective cohort study in patients with ESRD.
In comparison with surveys and retrospective studies,
prospective studies reduce selection biases, minimize any
influence of disease itself on the factor being investi-
gated, and may include better adjustment for potential
confounding factors. In this regard, it is important to note
that statistical adjustment for established risk factors was
incomplete in most studies in ESRD [17–19].
The presence of elevated IgA anti-C. pneumoniae titer
has been shown to reflect chronic chlamydia infection
[21], while it is unclear whether increased levels of IgG
antibodies reflect the duration of infection or reactivation
of a latent infection. Accordingly, most of the previously
reported studies in ESRD describing an association be-
tween chlamydia and atherosclerotic complications quan-
tified the severity of infection by measuring IgA antibodies.
In this prospective study, we found univariate associations
between survival and incident fatal cardiovascular events
with both IgA and IgG anti-C. pneumoniae titers and
IgA antibodies tended to be more strongly related to
these outcomes. However, after adjustment for age and
smoking, both IgA and IgG anti-C. pneumoniae titers
were no longer significant, suggesting that the link be-
tween all-cause and cardiovascular mortality and chla-
mydia serology is confounded by these risk factors. Sta-
tistical adjustment in observational studies should be
carefully performed because a true causal link may be
obscured by adjustment for covariate(s), which are in
the pathogenetic chain of events triggered by the factor
being evaluated [22]. However we found that C. pneu-
moniae antibodies lost most of their prediction power
after simple adjustment for age and smoking, which are
recognized confounding factors in the general population
[23]. Furthermore, models adjusted for traditional risk
factors or fully adjusted models were compatible with a
slight association or no association at all (no risk excess).
Overall, our results in patients with ESRD are similar
to observations by Danesh et al [23] and to a large pro-
spective study in 21,520 professional men aged 35 to 64
years who attended a private medical organization in
London [24]. Our study had a 80% power to detect a
HR equal to or greater than 1.50 with a P value 0.05.
Thus, we can reliably exclude any strong association
between C. pneumoniae IgA and IgG titers and all cause
and cardiovascular mortality in patients with ESRD.
Study limitations
We did not measure repeatedly anti-chlamydia anti-
bodies during the follow-up and therefore we could not
correct for possible underestimation due to fluctuations
in serum antibody titers within individuals over time
(regression dilution bias). Larger studies are still re-
quired to show associations of moderate or a slight de-
gree in patients with ESRD. Furthermore, our study
cohort was composed of middle age and old individuals.
Therefore our data cannot be extrapolated at younger
ages when associations between infectious agents and
cardiovascular complications seem to be stronger [25].
CONCLUSION
Chlamydia seropositivity is associated to shorter sur-
vival and incident fatal cardiovascular events in patients
with ESRD but these associations are in large part attrib-
utable to the link between chlamydia and well-estab-
lished, traditional risk factors. It is highly unlikely that
chlamydia infection is a major risk factor in patients with
ESRD.
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